On Wednesday, Shares of Cognizant Technology Solutions Corp (NASDAQ:CTSH), lost -0.14% to $64.75. The stock attained the volume of 2.84 million shares.
Cognizant (CTSH) declared it has been placed in the “Winner’s Circle” in the new HfS Research Blueprint Report: Insurance As-a-Service for its excellence in both execution and innovation for clients. HfS Research is a leading independent global analyst firm for the business and IT services industry.
The Blueprint report compares the offerings and capabilities of 19 leading insurance as-a-service providers, with particular focus on the insurance industry’s use of as-a-service platforms, commercial delivery models, robotic process automation and analytics. Service providers were rated on each of these on a number of differentiators under equally weighted categories of innovation and execution. Companies found to be leading in these categories are placed in the “Winner’s Circle.”
Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other.
Shares of Radius Health Inc (NASDAQ:RDUS), surged 8.73% to $54.15, during its last trading session.
Radius Health, Inc. (RDUS) declares positive top-line data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial, which showed that women with postmenopausal osteoporosis (PMO) who received 18 months of daily abaloparatide (ABL) subcutaneous (SC) injection practiced a 70 percent reduction in the incidence of major osteoporotic fractures contrast to placebo. Responder analysis showed greater enhances in bone mineral density (BMD) at three combined anatomical sites (total hip, femoral neck and lumbar spine) contrast to placebo or teriparatide (TPTD) at 6, 12 and 18 months. These results, together with positive pharmacokinetic data from a study evaluating the ABL transdermal patch, were presented during the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting as oral and poster presentations, respectively.
“The Phase 3 ACTIVE trial found that women who were taking abaloparatide practiced an early risk reduction for major osteoporotic fractures,” said Dr. Lorraine Fitzpatrick, Chief Medical Officer at Radius Health. “These data could be important to patients who have raised skeletal fragility and greater risk of additional fractures.”
ACTIVE is a randomized, double-blind, placebo controlled Phase 3 trial evaluating fracture prevention in more than 2,400 women suffering from PMO.
Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States.
Finally, Viacom, Inc. (NASDAQ:VIAB), ended its last trade with 1.20% gain, and closed at $47.08.
The stock closed at a distance of 4.55% from 20-day simple moving average. In the last trading session, the stock’s price moved -22.38% below its 200 day moving average, changing hands as low as $46.15 per share. The stock is presently trading 7.17% above its SMA 50.
Viacom Inc. operates as an entertainment content company in the United States and internationally. The company creates television programs, motion pictures, short-form video, applications, games, consumer products, social media, and other entertainment content.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
